Stock SYNTA PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Synta Pharmaceuticals Corp. Nasdaq

Equities

US87162T2069

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Synta Pharmaceuticals Corp.
Apr. 22 BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
Apr. 22 BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT

Business Summary

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.

Managers

Managers TitleAgeSince
Edward Chiang FOU
 Founder - 11-08-31
William Sibold CEO
 Chief Executive Officer - 23-09-07
Rebecca Taub FOU
 Founder 71 16-06-30
Ronald Filippo CTO
 Chief Tech/Sci/R&D Officer - Nov. 20
Stephen Dodge CTO
 Chief Tech/Sci/R&D Officer - -
Paul Friedman BRD
 Director/Board Member 81 16-07-21
Tina Ventura IRC
 Investor Relations Contact - Jan. 28
Carole Huntsman PRN
 Corporate Officer/Principal - -
Dominic F. Labriola PRN
 Corporate Officer/Principal - 22-01-09
Robert Waltermire PRN
 Corporate Officer/Principal 60 21-08-01

Members of the board

Members of the board TitleAgeSince
Fred Bernard Craves FOU
 Founder 78 11-08-31
Julian Baker CHM
 Chairman 57 23-06-14
Ken Bate BRD
 Director/Board Member 73 16-07-21
Paul Friedman BRD
 Director/Board Member 81 16-07-21
Richard Levy BRD
 Director/Board Member 66 16-08-10
Rebecca Taub FOU
 Founder 71 16-06-30
William Sibold CEO
 Chief Executive Officer - 23-09-07
James Daly BRD
 Director/Board Member 63 19-06-26
Raymond Cheong BRD
 Director/Board Member 42 23-06-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 20,971,580 18,882,541 ( 90.04 %) 0 90.04 %

Shareholders

NameEquities%Valuation
Janus Henderson Investors US LLC
14.59 %
2,902,050 14.59 % 775 M $
Baker Bros. Advisors LP
9.900 %
1,969,798 9.900 % 526 M $
Baker Bros. Advisors LP
9.900 %
1,969,798 9.900 % 526 M $
Avoro Capital Advisor LLC
9.493 %
1,888,888 9.493 % 504 M $
Vanguard Fiduciary Trust Co.
7.914 %
1,574,742 7.914 % 421 M $
BlackRock Advisors LLC
5.777 %
1,149,559 5.777 % 307 M $
Rebecca Taub
5.601 %
1,114,539 5.601 % 298 M $
Paulson & Co., Inc.
5.557 %
1,105,741 5.557 % 295 M $
Paul Friedman
4.745 %
944,226 4.745 % 252 M $
RTW Investments LP
4.097 %
815,191 4.097 % 218 M $
NameEquities%Valuation
Baker Bros. Advisors LP
100.00 %
1,969,797 100.00 % 526 M $

Company contact information

Madrigal Pharmaceuticals, Inc.

200 Barr Harbor Drive Suite 200

19428, West Conshohocken

+267 824 2827

http://www.madrigalpharma.com
address Synta Pharmaceuticals Corp.

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-0.49% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.31% 96.73B
ARGENX SE Stock argenx SE
+1.66% 21.31B
BIONTECH SE Stock BioNTech SE
-16.16% 21.21B
GENMAB A/S Stock Genmab A/S
-6.82% 18.79B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.41% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-22.87% 13.68B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.32% 13.44B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.46% 10.98B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Stock
  5. Company Synta Pharmaceuticals Corp.